List of Excipients in Branded Drug SCOPOLAMINE

« Back to Dashboard

Generic Drugs Containing SCOPOLAMINE

Company	Ingredient	NDC	Excipient
Mylan Pharmaceuticals Inc	scopolamine	0378-6470	COPOVIDONE K25-31
Mylan Pharmaceuticals Inc	scopolamine	0378-6470	D&C BLACK NO. 2
Mylan Pharmaceuticals Inc	scopolamine	0378-6470	DIMETHICONE
Mylan Pharmaceuticals Inc	scopolamine	0378-6470	DOCUSATE SODIUM
Mylan Pharmaceuticals Inc	scopolamine	0378-6470	FERRIC OXIDE RED

What are the Most Frequently-Used Excipients in SCOPOLAMINE?

# Of NDCs	Excipient
2	CINQUASIA RED
2	COPOVIDONE K25-31
5	CROSPOVIDONE
4	D&C BLACK NO. 2
5	DIMETHICONE

Scopolamine Excipient Strategy and Commercial Opportunities

Last updated: August 9, 2026

Scopolamine offers the clearest formulation opportunity in transdermal delivery. The marketed system uses a low-dose, multi-day patch containing scopolamine hydrobromide, light mineral oil, and polyisobutylene. The core commercial opportunity is not a new active ingredient. It is a differentiated delivery system that improves adhesion, reduces skin reactions, supports heat and humidity stability, or expands use into hospital, perioperative, pediatric, and travel-health settings.

The U.S. reference product, Transderm Scop, delivers approximately 1 mg of scopolamine over three days from a 1.5-mg patch. Its FDA-approved indications are prevention of nausea and vomiting associated with motion sickness and prevention of postoperative nausea and vomiting in adults when administered before surgery [1]. The historic transdermal patent estate has largely expired, leaving formulation execution, regulatory strategy, manufacturing capability, and clinical usability as the main barriers to entry.

What is scopolamine and which dosage forms are commercially relevant?

Scopolamine, also called hyoscine, is a centrally acting muscarinic antagonist. Scopolamine hydrobromide is the most relevant pharmaceutical salt for finished-dose development.

Dosage form	Commercial status	Main opportunity	Principal technical barrier
Transdermal patch	Established U.S. product	Generic substitution and improved patch design	Controlled flux, adhesion, irritation
Injectable solution	Established hospital product in selected markets	Perioperative and palliative-care supply	Sterility, dosing, abuse and handling controls
Oral tablets or capsules	Limited commercial relevance	Niche regional products	Low and variable oral tolerability
Buccal or sublingual system	Development opportunity	Rapid onset without injection	Taste, dose uniformity, mucosal irritation
Intranasal system	Development opportunity	Rapid rescue or acute nausea treatment	Local tolerability and short residence time
Microneedle or wearable patch	Early-stage opportunity	Pediatric, hospital, and continuous delivery	Device complexity, cost, regulatory classification

The transdermal route remains the most attractive because scopolamine is potent, requires a low daily dose, and benefits from avoidance of gastrointestinal absorption. The patch also avoids the frequent dosing required by oral products.

What excipients are used in the marketed scopolamine patch?

The labeled Transderm Scop system contains scopolamine, light mineral oil, and polyisobutylene in the drug reservoir or adhesive matrix, depending on the product configuration [1, 2].

Excipient or material	Functional role	Commercial significance
Light mineral oil	Plasticizer and vehicle	Controls matrix softness and drug mobility
Polyisobutylene	Pressure-sensitive adhesive and matrix component	Supports skin contact and drug release
Polyester or polymeric backing	Structural support and occlusion control	Affects moisture transmission and wear time
Rate-controlling membrane, where used	Regulates drug flux	Creates an important formulation-development variable
Release liner	Protects adhesive before application	Requires low extractables and clean peel behavior

The key excipient issue is balance. Increasing plasticization can improve scopolamine mobility but may reduce cohesive strength, increase cold flow, or alter adhesion during heat exposure. Increasing adhesive cohesion can reduce drug release. A successful generic or lifecycle product must match delivery performance without reproducing every material choice of the reference product.

The FDA label does not establish that every physical component has the same regulatory status as an inactive ingredient in an oral dosage form. For a transdermal product, polymers, backing films, membranes, liners, and adhesives are part of the drug-delivery system and must be characterized as components of the finished product [1].

How should an excipient strategy be designed for scopolamine patches?

A practical excipient strategy should begin with the target product profile rather than with a search for substitute polymers.

Release control

The target is approximately continuous delivery over 72 hours. Development teams should control:

• Scopolamine salt solubility in the adhesive phase
• Drug partitioning between matrix, membrane, and skin
• Polymer glass-transition behavior
• Adhesive thickness and coating weight
• Crystallization during storage
• Release changes after exposure to heat and humidity

Scopolamine is a low-dose drug, so small changes in drug loading, coating weight, or patch area can materially affect delivery. The formulation should be evaluated using both in vitro release testing and in vitro permeation testing. A release profile alone does not establish equivalent skin permeation.

Adhesion

A patch that delivers the correct average dose but detaches during travel, bathing, sweating, or sleep has poor commercial value. Adhesive screening should include:

• Initial tack
• Peel adhesion
• Shear resistance
• Edge lift after 72 hours
• Adhesion after immersion or shower exposure
• Performance on oily, dry, hairy, and mature skin
• Residue after removal

Polyisobutylene remains attractive because of its established use in transdermal systems and relatively low volatility. Acrylic and silicone adhesives may provide alternative adhesion profiles, but each creates a different extractables, irritation, and regulatory package.

Skin tolerability

Scopolamine patches are applied behind the ear, where prolonged contact can produce erythema, pruritus, or adhesive-related dermatitis. Commercial differentiation can come from reducing:

• Residual adhesive
• Occlusion
• Skin stripping during removal
• Irritating monomers or low-molecular-weight fractions
• Permeation-enhancing excipients
• Local drug crystallization

A hypoallergenic positioning requires evidence. Replacing a known adhesive with a new polymer is not inherently safer and may require broader sensitization and irritation testing.

Stability

The formulation must protect scopolamine from changes caused by moisture, heat, oxygen, and light. Packaging is part of the excipient and device strategy. Individual foil pouches can limit moisture ingress and volatile loss. Stability programs should include:

• Long-term and accelerated storage
• Open-pouch hold time
• Heat exposure during shipping
• Humidity cycling
• Drug crystallization
• Adhesive migration
• Pouch seal integrity
• Dose uniformity across the patch

For a generic product, the stability package must support the proposed shelf life and demonstrate that the delivery system remains within specification through the labeled wear period.

What formulation patents protect scopolamine delivery systems?

The historic patent position is strongest around transdermal architecture rather than around scopolamine as a molecule.

Patent area	Typical protected subject matter	Present commercial relevance
Reservoir patch	Drug reservoir, membrane, backing, and adhesive arrangement	Foundational patents are generally expired
Matrix patch	Polymer matrix containing scopolamine and pressure-sensitive adhesive	Can remain relevant only if later claims or country-specific rights survive
Controlled-flux membrane	Membrane composition and permeability range	Important for design-around analysis
Patch geometry	Area, drug loading, and delivery rate	Relevant to equivalence and infringement risk
Packaging	Moisture barrier and individual pouch construction	Usually lower-value unless narrowly claimed
Combination therapy	Scopolamine with another antiemetic	Potential method-of-use or formulation opportunity

U.S. Patent No. 4,292,299 is a historical patent associated with transdermal therapeutic systems and is commonly cited in the development history of scopolamine patches [3]. Its original patent term has expired. A freedom-to-operate review still must cover later patents directed to adhesive chemistry, polymer matrices, patch geometry, manufacturing processes, and combination products in each target jurisdiction.

The strongest current IP strategy is likely to involve a narrow but commercially defensible improvement, such as:

• A low-irritation adhesive composition
• A patch that maintains adhesion in water or high humidity
• A reduced-residue matrix
• A lower-dose patch with equivalent exposure
• A pediatric or small-area patch
• A rapid-onset buccal or intranasal system
• A manufacturing process that improves content uniformity
• A tamper-resistant hospital presentation

Broad claims to "scopolamine in a transdermal patch" face substantial prior-art exposure.

When does scopolamine lose exclusivity?

The principal U.S. product has no meaningful remaining new chemical entity exclusivity. The original Transderm Scop product was approved long ago, and the historic transdermal patent protection has expired.

Exclusivity category	Scopolamine status
New chemical entity exclusivity	Expired
Original transdermal patent protection	Expired or commercially exhausted in the United States
Pediatric exclusivity	No current material protection identified
Orphan exclusivity	Not applicable to the principal indications
Reference-product exclusivity	No current barrier comparable to a recent branded launch
Device or formulation exclusivity	Potentially available only through new qualifying claims or regulatory pathways

FDA generic entry therefore depends primarily on ANDA requirements, product-specific equivalence, manufacturing capacity, and any live listed patents or regulatory exclusivities associated with the reference product [4].

What is the Orange Book status of scopolamine?

The U.S. reference product is Transderm Scop, associated with NDA 017874. The Orange Book is the controlling source for current listed patents, therapeutic-equivalence evaluations, and application status [4].

For a prospective ANDA sponsor, the critical checks are:

1. The current reference-listed drug and dosage form.
2. Whether the reference product remains active for the intended strength and route.
3. Any listed patents and their expiration dates.
4. Whether a Paragraph IV certification is required.
5. Whether the product has a designated reference standard for ANDA development.
6. Whether FDA has granted therapeutic-equivalence ratings to existing generic transdermal systems.

The Orange Book position can change through patent-listing updates, application transfers, discontinued-product determinations, or new generic approvals. Regulatory teams should treat the live FDA record, not historical commercial databases, as authoritative.

Which companies are challenging or competing with branded scopolamine?

Competition is fragmented because scopolamine is a mature product with a limited number of differentiated dosage forms.

Competitor group	Product strategy	Competitive pressure
Generic transdermal manufacturers	AB-rated or therapeutically equivalent patches	Highest direct pressure
Branded patch suppliers	Supply continuity, packaging, and pharmacy relationships	Moderate
Hospital injectable suppliers	Perioperative and institutional use	High in acute-care settings
Oral antiemetic manufacturers	Ondansetron, meclizine, dimenhydrinate, promethazine	High substitution pressure
Long-acting antiemetic developers	New delivery systems and combination products	Potential future pressure
Compounding pharmacies	Patient-specific formulations	Limited, jurisdiction-dependent

Scopolamine competes clinically with meclizine, dimenhydrinate, promethazine, ondansetron, dexamethasone, and neurokinin-1 antagonists. Its principal advantages are multi-day delivery and avoidance of repeated oral dosing. Its disadvantages include anticholinergic adverse effects, blurred vision, dry mouth, confusion, urinary retention, and contraindication concerns in some older patients.

What Paragraph IV challenges and litigation risks exist?

A Paragraph IV challenge would normally arise if the Orange Book lists an unexpired patent covering the reference product. For the mature Transderm Scop product, the commercial importance of a Paragraph IV case depends on whether a later-listed patent covers a material formulation, manufacturing process, or use.

The principal litigation risks are:

• Infringement claims against a patch matrix or adhesive composition
• Regulatory litigation over ANDA approval timing
• Trade-secret disputes involving coating and lamination processes
• Product-liability litigation involving anticholinergic adverse effects
• False advertising disputes concerning adhesion, wear time, or lower irritation
• Patent disputes over combination use in postoperative nausea and vomiting

The settlement value of any Paragraph IV case would depend on the identity of the listed patent, its remaining term, the number of approved generics, and the likelihood that the patent survives validity and claim-construction challenges. No broadly reported, high-value settlement has defined the current scopolamine patch market in the sources cited here.

What FDA regulatory pathway applies to a new scopolamine patch?

A follow-on transdermal product generally requires an ANDA if it can demonstrate pharmaceutical equivalence and bioequivalence to the reference product. The development package typically includes:

• Same active ingredient and route
• Same dosage form and strength
• Comparative composition
• In vitro release testing
• Adhesion assessment
• In vitro permeation testing where applicable
• Pharmacokinetic bioequivalence
• Extractables and leachables data
• Stability and package-integrity data
• Human factors information for application and removal

A materially different patch may require a 505(b)(2) application rather than an ANDA. This route may support changes in dose, wear duration, onset, patch area, delivery technology, or indication, but it usually requires additional clinical or bridging evidence [5].

A new buccal, nasal, injectable, or microneedle product would generally require a 505(b)(2) application or a full new drug application, depending on the extent of reliance on existing findings.

What commercial opportunities exist for excipient suppliers?

Excipient suppliers can create value without owning the active pharmaceutical ingredient by offering an integrated transdermal platform.

High-value opportunities

• Polyisobutylene systems with improved wet adhesion
• Low-residue adhesives for three-day wear
• Prequalified medical-grade adhesive blends
• Moisture-resistant pouch and liner systems
• Polymer systems that limit scopolamine crystallization
• Coating processes for low-dose content uniformity
• Solvent-free or reduced-solvent manufacturing
• Skin-friendly systems supported by irritation and sensitization data
• Regulatory documentation packages for ANDA and 505(b)(2) sponsors

The most attractive supplier model combines excipient supply with formulation know-how, coating-process support, analytical methods, and regulatory documentation. A commodity polymer alone is more vulnerable to substitution.

How does scopolamine compare with competing antiemetic products?

Attribute	Scopolamine patch	Oral meclizine	Oral or injectable ondansetron	Injectable promethazine
Delivery interval	Up to three days	Repeated dosing	Repeated or acute dosing	Acute dosing
Route advantage	Avoids gastrointestinal absorption	Oral convenience	Strong acute-care use	Hospital and acute-care use
Main formulation opportunity	Adhesive and flux control	Taste, disintegration, dosing	Stability and combination therapy	Injectable safety and supply
Main safety concern	Anticholinergic effects	Sedation and anticholinergic effects	QT and constipation concerns	Sedation and tissue injury risk
Best commercial setting	Travel and selected perioperative use	Self-care motion sickness	Hospital and outpatient nausea	Hospital use

Scopolamine has a delivery advantage rather than a broad efficacy advantage. Commercial growth depends on patient preference, prescribing protocols, and supply reliability.

What manufacturing and geographic barriers affect market entry?

The product is technically simple compared with biologics but more difficult than a conventional tablet. Key manufacturing capabilities include precision coating, lamination, die cutting, pouching, and in-process content-uniformity control.

Geographic considerations include:

• U.S. ANDA or 505(b)(2) requirements
• European national or centralized regulatory strategy
• Country-specific recognition of transdermal generic equivalence
• Local patent and utility-model rights
• Differing excipient acceptability standards
• Medical-device integration requirements
• Reimbursement and pharmacy substitution rules
• Import controls for active pharmaceutical ingredient and coated web

Manufacturers with existing transdermal infrastructure have a cost advantage. A new entrant using contract manufacturing can reduce capital requirements but may face capacity constraints, technology-transfer risk, and limited control over coating parameters.

What generic launch scenarios exist for scopolamine?

Scenario 1: Standard AB-rated patch

This is the fastest path where the sponsor can match the reference product in composition, performance, and delivery. Price competition would likely be substantial, with supply reliability becoming a primary differentiator.

Scenario 2: Improved-adhesion patch

A modified adhesive system could support a 505(b)(2) strategy or an ANDA if the product remains pharmaceutically equivalent and bioequivalent. The commercial case depends on measurable reduction in detachment and acceptable skin tolerability.

Scenario 3: Lower-dose or smaller-area patch

A lower-dose product could target patients with adverse effects from standard dosing. It would require careful exposure and clinical-use justification and could avoid direct price competition if positioned as a differentiated product.

Scenario 4: Rapid-onset mucosal product

A buccal or intranasal product could address acute nausea where a patch is too slow. The opportunity is larger technically but carries greater clinical, local-tolerability, and regulatory risk.

Key Takeaways

• Scopolamine is a mature active ingredient with no meaningful new chemical entity exclusivity remaining.
• The principal U.S. commercial product is the Transderm Scop transdermal system.
• The marketed patch relies on scopolamine, light mineral oil, polyisobutylene, and polymeric delivery-system components.
• The strongest formulation opportunities are improved adhesion, reduced skin irritation, lower residue, heat and humidity stability, and better content uniformity.
• Broad claims to scopolamine patches face expired foundational prior art.
• A generic patch is primarily an execution and regulatory-equivalence opportunity.
• A materially different patch, buccal product, nasal product, or microneedle system would more likely require a 505(b)(2) pathway.
• The commercial market is exposed to generic price competition and substitution by oral and injectable antiemetics.
• Excipient suppliers can capture more value by combining polymers with coating technology, analytical support, and regulatory documentation.
• The most defensible IP is likely to cover a specific adhesive, matrix, delivery profile, manufacturing process, or differentiated patient-use feature.

FAQs

Is scopolamine hydrobromide suitable for transdermal delivery?

Yes. Its potency and low daily dose make it suitable for a multi-day transdermal system, provided the formulation controls skin flux, adhesion, and dose uniformity.

Can a new scopolamine patch use different excipients from Transderm Scop?

Yes, if the sponsor demonstrates pharmaceutical equivalence or establishes the product through an appropriate 505(b)(2) pathway. Different excipients may affect adhesion, permeation, irritation, and bioequivalence.

Is there biosimilar risk for scopolamine?

No. Scopolamine is a small-molecule drug, so the relevant competitive pathway is generic or 505(b)(2) development, not biosimilar approval.

What is the most valuable scopolamine patent strategy?

A narrow patent covering a clinically meaningful improvement, such as wet adhesion, lower irritation, controlled onset, reduced dose, or a specific polymer matrix, is more credible than a broad patent covering scopolamine transdermal delivery generally.

Which excipient is most important in a scopolamine patch?

Polyisobutylene is central to the marketed system because it contributes to both adhesion and drug-release behavior. Its replacement or modification should be evaluated as a complete delivery-system change, not as a simple inactive-ingredient substitution.

References

1. U.S. Food and Drug Administration. (2023). Transderm Scop: Prescribing information.
2. National Library of Medicine. (2024). DailyMed: Transderm Scop, scopolamine transdermal system.
3. Alza Corporation. (1981). Transdermal therapeutic system (U.S. Patent No. 4,292,299). U.S. Patent and Trademark Office.
4. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations: Orange Book.
5. U.S. Food and Drug Administration. (2019). Applications covered by Section 505(b)(2). FDA.